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1. Introduction 
Incidence of Colorectal Cancer: Colorectal cancer (CRC) is the third most common 
neoplasm worldwide. According to the International Agency for Research on Cancer 
(IARC), approximately 1.24 million new cases of CRC were detected worldwide in 2008 
(Ferlay, et al, 2008). It is the third most common cancer in men (10.0% of the total) and the 
second commonest in women (9.4% of the total) worldwide. IARC data have shown that 
more than half of all CRC cases occur in the developed regions of the world i.e. Europe, 
America and Japan (Ferlay, et al, 2008). In the European Union (EU27) alone 334,000 new 
cases of CRC were detected in 2008 and approximately 38,000 people were diagnosed with 
CRC in the UK alone (National UK Statistics). The incidence of CRC is on rise in Europe, 
particularly in southern and Eastern Europe, where rates were originally lower than in 
Western Europe (Coleman, et al, 1993 & Bray, et al, 2004). Contrary to the current trend in 
Europe, the incidence rate of CRC in the USA has fallen in the last two decades (NCI-SEER, 
2006). Epidemiological studies have identified that a rapid trend of ‘Westernization’, with 
change in diet and life style has resulted in increased incidence rates of CRC in developing 
countries (Marchand, et al, 1999, Flood, et al, 2000, Boyle, et al, 2008, & Ferlay, et al, 2010). 
The occurrence of CRC is strongly related to age, with nearly 80% of cases arising in people 
who are 60 years or older, although there has been a recent increase in incidence in people 
younger than 60. The lifetime risk for developing CRC in men is 1 in 16 whereas in women it 
is 1 in 20 (National Statistics, UK). 
2. The need for improved biomarkers  
The survival and prognosis of patients suffering from CRC depends on the stage of the 
tumour at time of detection. “Five year survival” significantly reduces from 93% for 
localized early cancerous lesions (Dukes A) to < 15% for advanced metastatic cancers 
(Dukes D). Unfortunately, approximately one third of patients with CRC have regional or 
distant spread of their disease at time of diagnosis (Ferlay, et al, 2008). Currently, bowel 
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cancer  screening programmes in Europe use either flexible sigmoidoscopy (FS) or guaiac-
based faecal occult blood testing (FOBT) as the primary screening tool, with the current gold 
standard colonic imaging modality of colonoscopy being reserved for patients testing 
positive. Both primary screening tests have proven to be of benefit in reducing the death 
rate from CRC in randomised controlled trials but are generally considered to lack the 
desired convenience or accuracy for use as a general screening test (Hewitson, et al, 2007). A 
comparative study of diagnostic sensitivities of FOBT, faecal immunochemical stool testing 
(FIT), flexible sigmoidoscopy (FS), colonoscopy and CT colonography (CTC) has revealed 
20%, 32%, 83.3% 100% and 96.7% sensitivity, respectively for the detection of CRC and 
advanced adenomas (Graser, et al, 2009) . Endoscopic and radiological diagnostic modalities 
are expensive and are associated with risks such as bleeding, infection, bowel perforation 
and exposure to radiation. This explains why there is still a need for an improved, reliable, 
accurate and non-invasive biomarker for colorectal cancer detection. 
3. Colorectal cancer development  
The development of CRC follows the sequential progression from adenoma to the 
carcinoma (Vogelstein, et al, 1988). Carcinogenesis pathways for colorectal neoplasia have 
become much clearer and precise in the past two decades. The common pathway for CRC 
development is dependent on Adenomatous Polyposis Coli (APC) & Tumour Protein-53 
(TP53) gene mutations and is initiated through WNT signalling (Segditsas, et al, 2006). In 
this pathway colonic carcinoma originates from the colonic epithelium as a consequence of 
accumulation of genetic alterations in the tumour suppressor gene TP53 and oncogenic APC 
genes. The initial genetic alterations result in adenoma formation in which cells exhibit 
autonomous growth. During the further course of carcinogenesis, intestinal epithelial cells 
acquire the characteristics of invasion and the potential for metastasis. Another 
carcinogenesis pathway has recently gained acceptance and is commonly named as the 
serrated-neoplasia pathway. This pathway is for the most part APC and TP53 independent 
and shows distinct molecular features of somatic mutations such as BRAF mutation and 
concordance with high CpG islands methylation phenotype (CIMP-H), microsatellite 
instability (MSI+) and MutT homologue 1 (MLH1) methylation (Casey, et al, 2005 & Spring, 
et al, 2006,) . Sequential progression of colorectal neoplasia from adenoma to carcinoma 
highlights that opportunities exist to improve cancer specific survival by altering the natural 
course of disease development. Such interventions could potentially be chemo preventive 
for high risk individuals, the early detection of colorectal neoplasia, chemotherapy to down 
stage the cancer prior to surgical resection and therapy for palliation of symptoms in 
advanced stage cancer. Recent advances in proteomics and genomics provide a vast amount 
of information about the role of micro-molecules in several cancer related pathways. These 
advances have focused on the detection of micro molecules released from tumour cells and 
their utility as diagnostic biomarkers.  The discovery of tumour specific microRNAs 
(miRNAs) has opened a new era of biomarker research that holds great potential for future 
cancer detection strategies.  
4. What are MicroRNAs  
MicroRNAs are single-stranded, evolutionarily conserved, small (17–25 ribonucleotides) 
noncoding (Lee, et al, 1993) RNA molecules. MiRNAs function as negative regulators of 
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target genes by directing specific messenger RNA cleavage or translational inhibition 
through the RNA induced silencing complex (RISC) (Bartel, et al, 2004 & 2009). So far 
around 1400 mature human miRNAs have been described in the Sanger miRBase version 17 
(An international registry and database for miRNA nomenclature, targets, functions and 
their implications in different diseases). In the database, each mature miRNA in human and 
non-human species is assigned a unique identifier number for universal standardization. 
For example human microRNA 21 is designated as hsa-miR-21. Table 1 summarizes the 
different types of RNAs by size, mechanism of action and function in human cells. 
Types of Non 
Coding RNA 
Size  
No of 
Nucleotides
Mechanism of Action Function 
MicroRNA 
(miRNA) 
17-23   RNA induced silencing 
complex (RISC) 
Translational Inhibition   
Messanger RNA 
(mRNA) 
900-1500 Conveys genetic 
information from DNA to 
the ribosomes 
Protein synthesis 
Small interfering 
RNA  (SiRNA) 
20-25 
Double 
stranded    
RNA interference and 
RNA interference related 
pathways 
Interference with gene 
expression  
Piwi-interacting 
RNA (piRNA)  
 
26-31  RNA-protein complex 
formation with piwi 
proteins 
Transcriptional gene 
silencing of 
retrotransposons and other 
genetic elements in germ 
line cells   
Small Nucleolar 
RNA (SnoRNA) 
70-200 Act as ribonucleoprotein 
(RNP) complexes to guide 
the enzymatic modification 
of target RNAs at sites 
determined by RNA:RNA 
antisense interactions 
Chemical modifications of 
other RNAs e,g 
methylation, 
pseudouridylation 
Transfer RNA 
(tRNAs)  
 
73 to 93  
Clover Leaf  
Transfers a specific active 
amino acid to a growing 
polypeptide chain at the 
ribosomal site of Protein 
Amino acid carriers and 
protein synthesis during 
translation. 
Ribosomal RNA 
( rRNA) 
120-5050 Decode mRNA into amino 
acids 
Protein synthesis in 
ribosomes 
Table 1. 
5. MicroRNA biogenesis in human cells  
MiRNAs are mostly transcribed from intragenic or intergenic regions by RNA polymerase II 
into primary transcripts (pri-miRNAs) of variable length (1 kb- 3 kb). In the nucleus Pri-
miRNA transcript is further processed by the nuclear ribo-nuclease enzyme ‘Drosha’ 
thereby resulting in a hairpin intermediate of about 70–100 nucleotides, called pre-miRNA. 
The pre-miRNA is then transported out of the nucleus by a transporting protein exportin-5. 
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In the cytoplasm, the pre-miRNA is once again processed by another ribonuclease enzyme 
‘Dicer’ into a mature double-stranded miRNA. The two strands of double stranded miRNA 
(miRNA/miRNA* complex) are separated by Dicer processing. After strand separation, the 
mature miRNA strand (miRNA- also called the guide strand) is incorporated into an RNA-
induced silencing complex (RISC), whereas the passenger strand, denoted with a star 
(miRNA*) is commonly degraded (Hammond, et al, 2000, Lee, et al, 2003, Bohnsack, et al, 
2004 & Thimmaiah, et al, 2005). This miRNA/RISC complex is responsible for miRNA 
function. If on miRNA cloning or array the passenger strand is found at low frequency (less 
than 15% of the guide strand) it is named miR*. However, if both passenger and guide 
strand are equal in distribution, then these two strands are named 3p and 5p version of 
miRNA depending on their location to either 5' or 3' of the miRNA molecule. In this case 
both strands can potentially incorporate in RISC complex and have a biological role. 
Nevertheless, quite a few miRNA* strands are found to be conserved and play an important 
role in cell homeostasis. However, only recently studies have focussed on the functional role 
of the miRNA* strand. Well-conserved miRNA* strands may prove important links in 
cancer regulation networks (Stark, et al, 2007, Okamura, et al, 2008, Zhou, et al, 2010 & Guo, 
et al, 2010). Figure 1 illustrates the biogenesis of miRNAs in the cellular nucleous, its 
transport to cytoplasm, and processing by Drosha and Dicer Enzymes. Figure 1 also 
illustrates the RISC incorporation of miRNAs for functional activity in different pathways of 
translational inhibition or activation.  
 
Fig. 1. 
6. Mechanism of action & cellular function of MicroRNA 
The specificity of miRNA targeting is defined by Watson–Crick complementarities between 
positions 2 to 8 from the 5 primed end of miRNA sequence with the 3′ untranslated region 
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(UTR) of their target mRNAs. When miRNA and its target mRNA sequence show perfect 
complementarities, the RISC induces mRNA degradation. Should an imperfect miRNA–
mRNA target pairing occur, translation into a protein is blocked (Bartel, et al, 2004 & 2009). 
Regardless of which of these two events occur, the net result is a decrease in the amount of 
the proteins encoded by the mRNA targets. Each miRNA has the potential to target a large 
number of genes (on average about 500 for each miRNA family). Conversely, an estimated 
60% of the mRNAs have one or more evolutionarily conserved sequences that are predicted 
to interact with miRNAs (Friedman, et al, 2009). MiRNAs have been shown to bind to the 
open reading frame or to the 5′ UTR of the target genes and, in some cases, they have been 
shown to activate rather than to inhibit gene expression (Ørom, et al, 2008). It has also 
reported that miRNAs can bind to ribonucleoproteins in a seed sequence and a RISC-
independent manner and then interfere with their RNA binding functions (decoy activity) 
(Eiring, et al, 2010). MiRNAs can also regulate gene expression at the transcriptional level by 
binding directly to the DNA (Khraiwesh, et al, 2010) as illustrated in Figure 1.  
7. Methods of MicroRNA analysis and quantification 
Numerous approaches have been developed to analyze and quantify the expression of 
miRNAs. A commonly adopted strategy is to perform mass scale expression 
profiling/signature of miRNAs on a small cohort of patients to identify most significantly 
dysregulated miRNAs. Expression profiling is usually followed by a validation of selected 
miRNAs on an independent cohort by using QRT-PCR. Expression profiling has been 
performed using Hybridization-Microarray, Real Time Polymerase Chain Reaction (QRT-
PCR) Array and most recently Deep-Sequencing (Meyer, et al, 2010). Most of these 
approaches are developed against the gold standard ‘Northern Blotting’. Each has its 
unique advantages and disadvantages, such as throughput, sensitivity, ease of use and 
cost. QRT-PCR can detect very low concentrations of molecules with much superior 
sensitivity and expenditure of time and money (Chen, et al, 2005). Microarray-based 
techniques have the advantage of being relatively cost-effective, quick and simple to 
utilize (Pradervand, et al, 2010). Ultra high throughput miRNA sequencing allows de-
novo detection and relative quantification of miRNAs, but requires a considerable amount 
of time and cost for data generation and data analysis (Wang, et al, 2007). A key issue of 
miRNA detection and quantification is the selection of endogenous controls for relative 
quantification. In QRT-PCR based detection systems, several small nuclear and small 
nucleolar RNAs (e.g. RNU6B) are recommended for normalising miRNA expression 
signature/profiles in tissues, cell lines, and human body fluids.  However, RNU6B is heat 
unstable and rapidly degrades resulting in poor reproducibility of experiments. That’s 
why many researchers have used the invariant and most stable miRNAs as endogenous 
controls (Meyer, et al, 2010). In order to overcome this problem of normalization in QRT-
PCR and other detection systems, researchers have used different statistical strategies 
including: global mean expression; quantile; scaling; and normalizing factor. However, 
some normalization methods have been challenged whereas others were adapted to the 
specific nature of miRNA profiling experiments. At present, there is no generally agreed 
normalization strategy for any of the known detection approaches. Table 2 shows the 
comparison of different detection systems by practical application, throughput, cost and 
time expenditure. 
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Detection Systems
 
MicroRNA QRT-PCR  
Expression Profiling 
MicroRNA- 
Array 
MicroRNA- 
Sequencing 
Method PCR Hybridization Deep Sequencing 
Initial RNA 
Concentration 
10ng 100 ng 250ng 
Time Required < 24 hours 24-48 hours >1 week 
Cost Low-medium for Pool 
Profiling. Even lower 
for custom designed 
individual assays. 
Low-medium for 
Pool Profiling 
 
High 
Throughput Medium-high High Ultra-high 
Utility 
 
Relative and absolute 
quantification of 
miRNAs 
Relative and 
absolute 
quantification of 
miRNAs 
Relative quantification 
of known miRNAs. 
Identification of  
novel miRNA 
sequences. 
Table 2. 
8. Role of MicroRNA in colorectal cancer development 
MiRNAs have been shown to play an important role in colorectal cancer oncogenesis, 
progression, angiogenesis, invasion and metastasis (Lee, et al, 2007, Huang, et al, 2008 & Liu, 
et al, 2011). Esquela-Kerscher & Slack in their review have suggested that the dysregulation 
of miRNA genes that target mRNAs for tumour suppressor or oncogenes can influence 
tumourigensis (Esquela-Kerscher, et al, 2006). The miRNA expression profiling studies on 
colonic tumour and adjacent normal tissue have identified several differentially expressed 
miRNAs in cancerous tissue. Table 1 summarizes the relatively over-expressed and under-
expressed miRNAs studied in CRC tissue from different studies. Studies focussing on the 
functional and mechanistic involvement of miRNAs in colon cancers have reported that 
selected groups of distinct miRNAs are commonly and concurrently upregulated or 
downregulated in colon cancer tissues and are often associated with distinct cytogenetic 
abnormalities (Xi, et al, 2006, Schepeler, et al, 2008 & Schetter, et al, 2008). Table 3 shows the 
summary of dysregulated miRNAs in colorectal tumour tissue compared to adjacent normal 
colonic mucosa. Over expressed or under expressed miRNAs identified by two or more 
studies are underlined and the miRNAs with conflicting expression levels in different 
studies are identified in Bold. 
 
Studies Downredulated miRNAs in 
CRC tissue  
Upregulated  miRNAs in CRC 
tissue 
Michael, et al,  2003 let-7, miR-16, miR-24, 
 miR-26a, miR-102,  
miR-143, miR-145,   
miR-200b 
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Studies Downredulated miRNAs in 
CRC tissue  
Upregulated  miRNAs in CRC 
tissue 
Volinia, et al,  2006 let-7a-1, miR-9-3, miR-23b,  miR-
138,  miR-218 
 
miR-16,  miR-17-5p, miR-20a, 
miR-21, miR-29b ,miR-141, miR-
195, miR-199a 
Xi, et al,  2006  let-7b, let-7 g , miR-26a , miR-
30a-3p, miR-132, miR-181a, 
miR-181b, miR-296, miR-320, 
miR-372  
miR-10a, miR-15b ,miR-23a, 
miR-25, miR-27a, miR-27b, miR-
30c, miR-107, miR-125a, miR-191, 
miR-200c, miR-339 
Bandrés. et al, 2006 miR-133b, miR-145 
 
miR-31, miR-96, miR-135b, miR-
183 
Akao, et al, 2006  miR-143, miR-145, let -7 
 
 
Nakajima, et al, 
2006 
 let-7 g, miR-181b, miR-200c 
 
Lanza, et al,  2007   miR-17-5p, miR-20, miR-25, miR-
92, miR-93-1, miR-106a 
Rossi, et al,  2007  
 
miR-200b, miR-210 , miR-224 
 
miR-19a, miR-20, miR-21, miR-23a, 
miR-25, miR-27a, miR-27b, miR-
29a, miR-30e, miR-124b, miR-132, 
miR-133a, miR-135b, miR-141, 
miR-147, miR-151, miR-152, miR-
182, miR-185 
Slaby, et al, 2007  
 
miR-31, miR-143, miR-145 miR-21 
Monzo, et al, 
 2008  
miR-145 miR-17-5p ,miR-21, miR-30c, miR-
106a, miR-107, miR-191, miR-221 
Schepeler, et al,  
2008  
miR-101,  miR-145, miR-455, 
miR-484 
miR-20a, miR-92, miR-510, miR-
513 
Schetter, et al,  
 2008  
 miR-20a, miR-21, miR-106a, miR-
181b, miR-203 
Arndt, et al, 2009  miR-1, miR-10b, miR-30a-3p,  
miR-30a-5p,  miR-30c, miR-125a, 
miR-133a, miR-139,  miR-143,  
miR-145,  miR-195,  miR-378*,  
miR-422a,  miR-422b, miR-497 
miR-17-5p,  miR-18a,  miR-19a,  
miR-19b, miR-20a,  miR-21,  
miR-25, miR-29a,  miR-29b,  
miR-31, miR-34a,  miR-93,  miR-
95, miR-96,  miR-106a,  miR-106b,  
miR-130b, miR-181b, miR-182,  
miR-183,  miR-203, miR-224 
Slattery, et al, 2011  miR-143, miR-145, miR-192, 
miR-215 
miR-21, miR-21*, miR-183, miR-
92a, miR-17, miR-18a, miR-19a, 
miR-34a 
Table 3. 
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9. The use of circulating satellite MicroRNA for colorectal cancer detection 
Recent work by Mitchell & Gilad (Mitchell, et al, 2008 & Gilad, et al, 2008) has identified the 
presence of cancer related miRNAs in the body fluids of patients with different body organ 
cancers. These tumour-derived miRNAs are present in human serum or plasma in a 
remarkably stable form and are protected from endogenous ribonuclease activity. Given 
that aberrantly expressed miRNAs in CRC tissue are secreted into blood, circulating 
miRNAs can potentially serve as non-invasive markers for CRC detection. In 2008, Chen 
and colleagues used high-throughput sequencing technique and compared the miRNA 
expression profiles of patient with CRC and healthy controls (Chen, et al, 2008). MiRNA 
expression profiles of CRC and healthy controls were significantly different. However, more 
than 75% of the aberrantly expressed miRNAs, detected in the serum of CRC patients were 
also present in the serum of patients with lung cancer. A similar trend was also observed in 
another study where expression profiles generated from plasma of breast cancer patients 
were compared with colorectal cancer and other solid organ cancers (Heneghan, et al, 2010). 
Identification and quantification of cancer related circulating miRNAs are associated with 
challenges in terms of sample preparation, experimental design, and pre-analytic variation, 
selection of diagnostic miRNAs, data normalization and data analysis. Meyer & Kroch 
(Meyer, et al, 2010 & Kroh, et al, 2010) have recently addressed many of these obstacles and 
provided a guide for effective strategies to overcome these issues. 
Preliminary studies (Ng, et al, 2009, Pu, et al, 2010 & Cheng, et al, 2011) suggest that 
colorectal tumour derived miRNAs are present in the circulation at detectable levels and can 
used as potential biomarkers for colorectal neoplasia detection. These studies used either 
whole plasma or total RNA extracted from a defined amount of plasma samples collected 
from healthy controls and diseased patients. QRT-PCR based detection systems were 
applied to detect selected circulating miRNAs. Selection of miRNAs was based either on 
results of plasma miRNA expression profiling experiments performed on  relatively small 
cohorts of healthy and diseased patients or highly up regulated miRNAs in CRC tissue. 
Table 4 summarizes the sensitivity and specificity of different miRNAs investigated for their 
utility as biomarkers. Results of these studies are very encouraging due to the high 
sensitivity for detection of CRCs and adenomas. The accuracy of miRNA based detection 
modalities is much higher than stool based detection modalities and may be comparable 
with endoscopic modalities. Furthermore, the ability to detect adenomas highlights the 
potential role of circulating miRNAs in bowel cancer screening. Therefore, in addition to a 
stand alone blood test for CRC, a miRNA based blood assay can be used as a replacement of 
FOBT in bowel cancer screening programmes. With its higher sensitivity and specificity, it 
may prove cost effective and help reduce the need for unnecessary colonic investigations. 
Table 4 shows the comparison of sensitivity and specificity of different miRNAs for their 
utility as biomarkers for detection of adenocarcinoma and adenoma*. QRT-PCR based 
quantification of miRNAs has been the preferred method of study in the majority of these 
studies. 
Though the analysis of circulating miRNAs in CRC patients has identified several diagnostic 
miRNAs, their diagnostic accuracy is still questionable. This is due to overlapping miRNA 
expression with other cancers, non-cancerous conditions and variability of individual 
miRNA expression with stage and grade of tumour. It is possible that common 
carcinogenesis-related miRNAs are shared by different types of tumours and investigators 
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Tissue 
Type 
Studies Participants Target 
MiRNAs  
Diagnostic Accuracy 
Sensitivity 
% 
Specificity 
% 
Whole 
Plasma 
 
Pu, et al, 2010 
CRC             (n=103)
 
Controls        (n=37) 
miR-221 86 41 
Plasma 
RNA 
  
Cheng , et al,  
2011  
 
CRC I-IV     (n=102)
 
Controls        (n=48) 
miR-141 66.7 80.8 
 
Ng, et al,  
2009  
CRC              (n=90) 
 
Controls        (n=40) 
miR-17-3p  64 70 
miR-92 89 70 
 
 
Huang, et al , 
2010  
CRC             (n=100)
 
Adenomas*   (n=37)
  
Controls        (n=59) 
miR-29 69 
 
62.2* 
89.1 
 
84.7* 
miR-92a 84 
 
64.9* 
71 
 
81.4* 
Table 4. 
are detecting cancer-related but not tissue specific miRNAs. Another explanation of the 
findings is that the detection of miRNAs released into the circulation originates in immune 
cells which occur as a result of a systemic immune response generated by the tumour 
causing abnormal proliferation of colonic cells (Dong, et al, 2011). This might also explain 
the finding of commonly dysregulated miRNAs in patients with CRC and Ulcerative Colitis 
(Pekow, et al, 2011). Furthermore, studies to date have focused on measuring the circulating 
levels of either single miRNAs or a subset of the known miRNAs. Due to the above reasons, 
a single miRNA based detection strategy would be rather ineffective whereas a CRC tissue 
specific expression signature generated from plasma or serum of patients with CRC and 
adenoma could be more informative and accurate. 
The recent discovery of exosome mediated transport of cancer related miRNAs into the 
circulation, has shifted the focus of miRNA studies towards the isolation of tissue specific 
circulating exosomes and their encompassed miRNAs.  Exosomes are membrane bound 
small vesicles (20 to 100 nm in diameter) of endocytic origin and are released by a variety of 
cells in both healthy and disease conditions (Théry, et al, 2002 & Keller, et al, 2006). 
Exosomes correspond to the internal vesicles of multivesicular bodies (MVBs) and are 
released in the extracellular environment upon fusion of MVBs with the plasma membrane, 
(Théry, et al, 2002 & Cocucci, et al, 2009). Since exosome formation includes two inward 
budding processes, exosomes maintain the same topological orientation as the cell, with 
membrane proteins on the outside and some cytosol on the inside. Exosomes contain 
cytoplasmic proteins, miRNAs and mRNA transcripts (Valadi, et al, 2007).    
The topical orientation of exosomal membrane may help in identification of their source by 
using surface antigen directed antibodies e.g. anti-MHCII. One drawback of this isolation 
method is that unless all the exosomes contain the specific surface antigen used for the  
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Fig. 2. 
isolation, only a fraction of the exosomes will be isolated. Circulating exosomes can also be 
isolated based on their size, density and surface proteins. A commonly used method of 
purifying exosomes involves removal of cells and debris with either a filtration process or 
by a series of centrifugations (differential centrifugation), followed by a final high speed 
centrifugation (ultracentrifugation) to pellet the exosomes. Exosomes have a specific density 
and can be purified by floatation in a sucrose density gradient or by sucrosedeuterium oxide 
(D2O) cushions. Another purification method is based on exosome size and utilizes 
chromatography. The size and characterisation of exosomes is performed by using  
transmission electron microscopy, immune-electronmicroscopy, flow cytometry and 
dynamic light scattering. Table 5 summarizes the exosome isolation and characterisation 
methods used by different groups to analyse exosomes specific to colorectal cancer cells and 
methods of isolation of circulating exosomes for miRNAs analysis for other cancers 
(Simpson, et al, 2009). There is, however, a growing need for a fast and reliable method that 
yields a highly purified exosome fraction. 
Based on this immunoaffinity strategy, several groups have isolated exosomes from the 
blood of patients with different cancers and have performed miRNA expression profiles on 
the total RNA isolated from these purified and probably tumour specific exosomes (Taylor, 
et al, 2008, Logozzi, et al, 2009 & Rabinowits, et al, 2009). Patients with cancer are found to 
have relatively higher quantities of exosome and encompassed miRNAs in the circulation 
Rabinowits, et al, 2009). The analysis of miRNAs extracted from circulating exosomes in 
patients with ovarian cancer, has been proven to be equivalent to ovarian tissue biopsies 
Taylor, et al, 2008). By using a similar approach of isolation and analysis, exosomal miRNAs 
in colorectal cancer can be evaluated for their diagnostic accuracy and may prove a 
breakthrough diagnostic modality.   
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Isolation and Characterisation of Colorectal Cancer Cell line Exosomes 
Studies   Colorectal 
Cancer  Cell 
lines 
Isolation method Characterisation and Validation of 
Exosome 
Huber, et al, 
200569 
SW403 
1869col 
CRC28462 
Differential 
Centrifugation 
 
Transmission Electron Microscopy   
Immune Electron Microscopy  
Fluorescence-activated cell sorting 
(FACS) 
Western Blotting 
Mathivanan, et 
al, 
201070 
LIM1215 Filtration, 
Diafiltration (5K) 
Ultracentrifugation 
Immuoaffinity 
Transmission Electron Microscopy  
Immune Electron Microscopy  
Western Blotting  
Choi, et al, 
200771 
HT29 Differential 
Centrifugation 
Diafiltration(100k) 
Density Gradient  
Transmission Electron Microscopy,  
Western Blotting   
van Nigel, et 
al, 200172 
HT29-19A 
T84- 
DRB1*0401/ 
CIITA 
Differential 
Centrifugation  
Density Gradient   
Transmission Electron Microscopy,  
Immune Electron Microscopy  
Western Blotting 
Isolation and Characterisation of Circulating Exosomes for MicroRNA Analysis 
Studies Cancer Type Isolation Method Specific Method/ Technique 
Logozzi, et al, 
200973 
Malignant 
Melanoma  
Ultracentrifugation 
and filtration 
400x g 20 min isolate plasma  
1,200x g20 min 
10,000x g 30 min and filter through 
0.22um  filter 
1,00,000x g 60 min 
Rabinowits, 
et  al, 200974 
Lung Cancer Immunoaffinity 
Ultracentrifugation  
anti-EpCAM coated Immunobead  
 
Taylor , et al, 
200875 
Ovarian 
Cancer 
Immunoaffinity 
Ultracentrifugation 
anti-EpCAM antibody coated 
Immunobead  
 
Table 5. 
10. The use of stool MicroRNAs for detection of colorectal neoplasia 
Colonic epithelium is the most dynamic cell population of the human organism. Highly 
differentiated colonocytes are continuously shed into the colon of healthy individuals and 
www.intechopen.com
 Biomarker 
 
12
patients with CRC (Brittan, et al, 2004 & Loktionov, et al, 2007) . It is presumed that 
exfoliated colonocytes from healthy colon and neoplastic lesions carry important genetic 
and epigenetic information that could be utilized for subsequent testing, such as the 
detection of mutant genes or dysregulated mRNAs, proteins and miRNAs (Loktionov, et al, 
2009). It is proposed that even small neoplastic loci can alter colonic cell exfoliation rate and 
may lead to early detection of these lesions (Loktionov, et al, 2007). The effectiveness of an 
exfoliated colonocyte based detection system requires an efficient isolation of colonocytes 
while minimizing the amount of background faecal debris. In order to achieve maximum 
retrieval of colonocytes, strategies that have been employed include density gradient 
centrifugation and/or immunoaffinity on either homogenized stool samples or scrapings 
from the stool surface (Loktionov, et al, 2007). However, cell yields are generally very low, 
often with conspicuous background debris, which makes cell identification difficult and 
time consuming (Deuter, et al, 1995). Consequently, such preparations would be unsuitable 
for high-throughput population screening programs (White, et al, 2009). Furthermore, 
colonocytes shed from a proximal colonic region travel a longer distance and are more 
exposed to cytolytic agents, thus making them less likely to be preserved and sampled. If 
this does prove to be a common problem, stool miRNA markers for right-sided CRC will be 
less effective. There is evidence, from the work of Koga and Colleagues (Koga, et al, 2010) 
that this is indeed the case. In this study immunomagnetic beads were conjugated with 
EpCAM monoclonal antibody to isolate colonocytes from stool. Despite the selection of two 
highly up regulated miRNAs in CRC cells, the sensitivity of detection was approximately 
70% as shown in table 6. However, the detection rate for left sided colonic and rectal tumour 
was significantly higher, suggesting the potential utility of exfoliated colonocytes based 
miRNA assay as an alternative to flexible sigmoidoscopy. It is well established that 
profound deregulation of apoptosis is a characteristic feature of cancer. As a result of 
apoptosis, tumour specific proteins and genetic information i.e. DNA, RNA and miRNA are 
released into the lumen of colon (Ahlquist, et al, 2010). Stool environment is much more 
complex and hostile than plasma, and human RNA are rapidly degraded and only 
constitute <1% of total stool RNA (Ahlquist, et al, 2010).  In contrast with the fast 
degradation of mRNA, human miRNAs are packed in micro vesicles and are well protected 
from degradation. The available data indicates that stool miRNA analysis can distinguish 
Tissue Type Studies Participants Target 
MiRNAs 
Diagnostic Accuracy 
Sensitivity 
%
Specificity
% 
Exfoliated 
Colonocytes 
Koga , et al, 
2010 
 
CRC         (n= 197) 
Control      (n=119) 
miR-17-92 
69.5 81.5 
miR-135 46.2 
 
95 
Faeces 
Link , et al, 
2010  
 
CRC             (n=10) 
 
Adenoma       (n=9) 
 
Control         (n=10)
miR-21 
 
miR-106 
Distinguished adenomas 
and carcinomas from 
healthy controls P<0.05 
Table 6. 
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adenoma and carcinoma from healthy controls (Link, et al, 2010). The detection of miRNAs 
in stool specimens requires efficient protocols for stool preparation, stool miRNA extraction 
and quantitative analysis (Ahmed, et al, 2009). The utility of stool miRNAs as a biomarker is 
still in its infancy; further studies of stool miRNA are needed on larger cohorts to validate its 
diagnostic accuracy.  
In summary, systemic and faecal miRNAs can accurately correlate with disease status and 
can potentially be used for colorectal cancer detection and screening. Detection of colorectal 
cancer based on miRNA expression analysis requires extensive pre analytical considerations 
for sample selection & processing, isolation of miRNAs, the method of expression analysis, 
selection of endogenous controls for normalisation and data analysis. Studies performed so 
far have shown great promise for miRNA based detection of colorectal carcinoma and 
adenoma. There is, however, a further need to develop and evaluate miRNA based assays 
before their clinical application.  
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